Billing and Coding MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (A58679) Final Billing and Coding Article - Effective August 08, 2022

This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).

Medicare Coverage Database (MCD) Number/Contractor Determination Number: A58679

Billing and Coding Article Title: Billing and Coding MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

Effective Date: August 08, 2022

Summary of LCA: The information in this article contains billing, coding or other guidelines that complement the Local Coverage Determination (LCD) for MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer L38972

Visit the Proposed LCDs webpage to access this Billing and Coding Article.

 

Last Updated Jun 22 , 2022